AbbVie Inc.
ABBV
शेयरों में रैंक
#25
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery,... AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
शेयर मूल्य
$282.96
मार्केट कैप
$500.02B
बदलाव (1 दिन)
-0.75%
बदलाव (1 वर्ष)
23.43%
देश
US
व्यापार AbbVie Inc. (ABBV)
श्रेणी
Healthcare
AbbVie Inc. (ABBV) के लिए लाभांश इतिहास
AbbVie Inc. (स्टॉक चिन्ह: ABBV) ने कुल 39 लाभांश भुगतान किए।
सभी लाभांशों का योग (स्टॉक स्प्लिट्स के लिए समायोजित) है: $45.62
लाभांश यील्ड (TTM): 0.0287
सभी लाभांशों का योग (स्टॉक स्प्लिट्स के लिए समायोजित) है: $45.62
लाभांश यील्ड (TTM): 0.0287
AbbVie Inc. (ABBV) के लिए 2016 से 2026 तक के लाभांश भुगतान
वार्षिक लाभांश भुगतान
| वर्ष | लाभांश (स्टॉक स्प्लिट समायोजित) | परिवर्तन |
|---|---|---|
| 2026 (TTM) | $1.49 | -73.97% |
| 2025 | $5.73 | -7.54% |
| 2024 | $6.20 | 4.73% |
| 2023 | $5.92 | 5.01% |
| 2022 | $5.64 | 8.42% |
| 2021 | $5.20 | 10.17% |
| 2020 | $4.72 | 24.23% |
| 2019 | $3.80 | 14.37% |
| 2018 | $3.32 | 35.02% |
| 2017 | $2.46 | 115.82% |
| 2016 | $1.14 | 0.00% |
सभी लाभांश भुगतानों की सूची
| वर्ष | लाभांश | परिवर्तन |
|---|---|---|
| 2026 (TTM) | $1.49 | -73.97% |
| 2025 | $5.73 | -7.54% |
| 2024 | $6.20 | 4.73% |
| 2023 | $5.92 | 4.96% |
| 2022 | $5.64 | 8.46% |
| 2021 | $5.20 | 10.17% |
| 2020 | $4.72 | 24.23% |
| 2019 | $3.80 | 14.37% |
| 2018 | $3.32 | 35.02% |
| 2017 | $2.46 | 115.82% |
| 2016 | $1.14 | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के लाभांश भुगतान
| कंपनी | लाभांश भुगतान की संख्या | देश |
|---|---|---|
| 215.00% |
US
|
|
| 225.00% |
US
|
|
| 223.00% |
US
|
|
| 33.00% |
CH
|
|
| 29.00% |
CH
|
